smokeless tobacco users who used Champix were significantly more likely to quit

The smoking cessation medication Champix has shown in many clinical trials to be an effective way to quit smoking cigarettes but a new study shows that it could also aid smokeless tobacco users too. The results of the research which were published by the British Journal of Medicine showed that those smokeless tobacco users who made use of Champix were significantly more likely to quit their habit than those participants who were only given the placebo.

The clinical trial which was carried out over twelve weeks used a double blind, randomized format involving 431 volunteers. Half of them were given Champix and the other half was given the placebo tablet. The results showed that between the weeks 9 and 12, 59% of those using the Champix had still quit tobacco use compared to only 39% using the placebo. 

The number of participants who were still not using tobacco at the end of the trial was 45% for those using the Champix and only 34% for those using the placebo. Another interesting observation made by the researchers was that former smokers who participated were much more probable to be successful in completely quitting from using smokeless tobacco than those participants who had never smoked in both the Champix and the placebo group.

Champix which is made by the pharmaceutical company Pfizer [which also makes Viagra] is an extremely effective smoking cessation medication which works by reducing cravings. Unlike many other smoking cessation methods you actually take the medication for a short while before you actually stop smoking.

Clinical trials show that people who use Champix are more likely to quit then those who don't and this prescription smoking cessation drug has been given approval by the Food & Drug Administration in America and also by the European Medicines Agency of the EU.